-
Je něco špatně v tomto záznamu ?
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
AFG. Cicero, A. Colletti, G. Bajraktari, O. Descamps, DM. Djuric, M. Ezhov, Z. Fras, N. Katsiki, M. Langlois, G. Latkovskis, DB. Panagiotakos, G. Paragh, DP. Mikhailidis, O. Mitchenko, B. Paulweber, D. Pella, C. Pitsavos, Ž. Reiner, KK. Ray, M....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
PubMed
28938795
DOI
10.1093/nutrit/nux047
Knihovny.cz E-zdroje
- MeSH
- dyslipidemie krev farmakoterapie epidemiologie MeSH
- fytonutrienty aplikace a dávkování krev farmakokinetika MeSH
- HDL-cholesterol krev MeSH
- intestinální absorpce účinky léků MeSH
- játra účinky léků metabolismus MeSH
- kardiovaskulární nemoci krev farmakoterapie epidemiologie MeSH
- LDL-cholesterol krev MeSH
- lékové interakce MeSH
- lidé MeSH
- medicína založená na důkazech MeSH
- metaanalýza jako téma MeSH
- nenasycené mastné kyseliny aplikace a dávkování krev farmakokinetika MeSH
- potravní doplňky * MeSH
- pozorovací studie jako téma MeSH
- probiotika aplikace a dávkování farmakokinetika MeSH
- randomizované kontrolované studie jako téma MeSH
- rizikové faktory MeSH
- statiny terapeutické užití MeSH
- triglyceridy krev MeSH
- životní styl MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.
1st Department of Internal Medicine Paracelsus Private Medical University Salzburg Austria
3rd Department of Internal Medicine 1st Medical Faculty Charles University Prague Czech Republic
Austrian Atherosclerosis Society
Baltic Atherosclerosis Society
Belgian Atherosclerosis Society
Biotechnology Research Center Mashhad University of Medical Sciences Mashhad Iran
Cardiology Clinic School of Medicine University of Athens Athens Greece
Cardiovascular Research Centre University of Zielona Gora Zielona Gora Poland
Chair for Internal Medicine Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Clinic of Cardiology University Clinical Centre of Kosovo Prishtina Kosovo
Croatian Atherosclerosis Society
Department of Cardiology University and Emergency Hospital Bucharest Romania
Department of Hypertension Chair of Nephrology and Hypertension Medical University of Lodz Poland
Department of Internal Medicine Centres Hospitaliers Jolimont Haine Saint Paul Belgium
Department of Internal Medicine Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Laboratory Medicine AZ Sint Jan Hospital Bruges Belgium
Department of Medicine and Surgery Sciences University of Bologna Bologna Italy
Department of Primary Care and Public Health Imperial College London UK
Dyslipidaemia Department Institute of Cardiology AMS of Ukraine Kiev Ukraine
Euro Mediterranean Institute of Science and Technology Palermo Italy
Hellenic Atherosclerosis Society
Hungarian Atherosclerosis Society
Italian Society of Nutraceuticals
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Baltimore Maryland USA
Lipid and Blood Pressure Meta Analysis Collaboration Group
Medical Faculty University of Prishtina Prishtina Kosovo
Polish Mother's Memorial Hospital Research Institute Lodz Poland
Preventive Cardiology CGH Medical Center Sterling Illinois USA
Romanian Society of Cardiology
Russian Cardiology Research and Production Centre Moscow Russia
Russian National Atherosclerosis Society
Serbian Association for Arteriosclerosis Thrombosis and Vascular Biology Research
Slovak Association of Atherosclerosis
Slovenian Society of Cardiology
Ukrainian Atherosclerosis Society
University of Medicine and Pharmacy Carol Davila Bucharest Romania
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010330
- 003
- CZ-PrNML
- 005
- 20180419145457.0
- 007
- ta
- 008
- 180404s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/nutrit/nux047 $2 doi
- 035 __
- $a (PubMed)28938795
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Cicero, Arrigo F G $u Department of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy; and Italian Society of Nutraceuticals.
- 245 10
- $a Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel / $c AFG. Cicero, A. Colletti, G. Bajraktari, O. Descamps, DM. Djuric, M. Ezhov, Z. Fras, N. Katsiki, M. Langlois, G. Latkovskis, DB. Panagiotakos, G. Paragh, DP. Mikhailidis, O. Mitchenko, B. Paulweber, D. Pella, C. Pitsavos, Ž. Reiner, KK. Ray, M. Rizzo, A. Sahebkar, MC. Serban, LS. Sperling, PP. Toth, D. Vinereanu, M. Vrablík, ND. Wong, M. Banach,
- 520 9_
- $a In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.
- 650 _2
- $a kardiovaskulární nemoci $x krev $x farmakoterapie $x epidemiologie $7 D002318
- 650 _2
- $a HDL-cholesterol $x krev $7 D008076
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 12
- $a potravní doplňky $7 D019587
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a dyslipidemie $x krev $x farmakoterapie $x epidemiologie $7 D050171
- 650 _2
- $a medicína založená na důkazech $7 D019317
- 650 _2
- $a nenasycené mastné kyseliny $x aplikace a dávkování $x krev $x farmakokinetika $7 D005231
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a intestinální absorpce $x účinky léků $7 D007408
- 650 _2
- $a životní styl $7 D008019
- 650 _2
- $a játra $x účinky léků $x metabolismus $7 D008099
- 650 _2
- $a metaanalýza jako téma $7 D015201
- 650 _2
- $a pozorovací studie jako téma $7 D064887
- 650 _2
- $a fytonutrienty $x aplikace a dávkování $x krev $x farmakokinetika $7 D064209
- 650 _2
- $a probiotika $x aplikace a dávkování $x farmakokinetika $7 D019936
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a triglyceridy $x krev $7 D014280
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Colletti, Alessandro $u Department of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy; and Italian Society of Nutraceuticals.
- 700 1_
- $a Bajraktari, Gani $u Clinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo; Medical Faculty, University of Prishtina, Prishtina, Kosovo; and Kosovo Society of Cardiology.
- 700 1_
- $a Descamps, Olivier $u Department of Internal Medicine, Centres Hospitaliers Jolimont, Haine Saint-Paul, Belgium; and Belgian Atherosclerosis Society.
- 700 1_
- $a Djuric, Dragan M $u Institute of Medical Physiology "Richard Burian," Faculty of Medicine, University of Belgrade, Belgrade, Serbia; and Serbian Association for Arteriosclerosis, Thrombosis and Vascular Biology Research.
- 700 1_
- $a Ezhov, Marat $u Russian Cardiology Research and Production Centre, Moscow, Russia; and Russian National Atherosclerosis Society.
- 700 1_
- $a Fras, Zlatko $u Preventive Cardiology Unit, Department of Vascular Medicine, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia; Chair for Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; and Slovenian Society of Cardiology.
- 700 1_
- $a Katsiki, Niki $u Second Department of Propaedeutic Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
- 700 1_
- $a Langlois, Michel $u Department of Laboratory Medicine, AZ Sint-Jan Hospital, Bruges, Belgium; and Belgian Atherosclerosis Society.
- 700 1_
- $a Latkovskis, Gustavs $u Faculty of Medicine and Institute of Cardiology and Regenerative Medicine, University of Latvia, Riga, Latvia; and Baltic Atherosclerosis Society.
- 700 1_
- $a Panagiotakos, Demosthenes B $u School of Health Science and Education, Department of Nutrition and Dietetics, Harokopio University of Athens, Athens, Greece.
- 700 1_
- $a Paragh, Gyorgy $u Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; and Hungarian Atherosclerosis Society.
- 700 1_
- $a Mikhailidis, Dimitri P $u Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London, London, UK.
- 700 1_
- $a Mitchenko, Olena $u Dyslipidaemia Department, Institute of Cardiology AMS of Ukraine, Kiev, Ukraine; and Ukrainian Atherosclerosis Society.
- 700 1_
- $a Paulweber, Bernhard $u 1st Department of Internal Medicine, Paracelsus Private Medical University, Salzburg, Austria; and Austrian Atherosclerosis Society.
- 700 1_
- $a Pella, Daniel $u 1st Department of Internal Medicine, Faculty of Medicine, Pavol Jozef Safarik University, Košice, Slovakia; and Slovak Association of Atherosclerosis.
- 700 1_
- $a Pitsavos, Christos $u Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece; and Hellenic Atherosclerosis Society.
- 700 1_
- $a Reiner, Željko $u University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Internal Medicine, Zagreb, Croatia; and Croatian Atherosclerosis Society.
- 700 1_
- $a Ray, Kausik K $u Department of Primary Care and Public Health, Imperial College, London, UK.
- 700 1_
- $a Rizzo, Manfredi $u Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy; and Euro-Mediterranean Institute of Science and Technology, Palermo, Italy.
- 700 1_
- $a Sahebkar, Amirhossein $u Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
- 700 1_
- $a Serban, Maria-Corina $u Center for Interdisciplinary Research, and Department of Functional Sciences, University of Medicine and Pharmacy "Victor Babes," Timisoara, Romania.
- 700 1_
- $a Sperling, Laurence S $u Division of Cardiology, Emory University, Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia, USA.
- 700 1_
- $a Toth, Peter P $u Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland, USA; and Preventive Cardiology, CGH Medical Center, Sterling, Illinois, USA.
- 700 1_
- $a Vinereanu, Dragos $u University of Medicine and Pharmacy "Carol Davila," Bucharest, Romania; Department of Cardiology, University and Emergency Hospital, Bucharest, Romania; and Romanian Society of Cardiology.
- 700 1_
- $a Vrablík, Michal $u Third Department of Internal Medicine, First Medical Faculty, Charles University, Prague, Czech Republic; and Czech Atherosclerosis Society.
- 700 1_
- $a Wong, Nathan D $u Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, California, USA.
- 700 1_
- $a Banach, Maciej $u Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland; Polish Mother's Memorial Hospital Research Institute, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland; Lipid and Blood Pressure Meta-Analysis Collaboration Group; and Polish Lipid Association.
- 773 0_
- $w MED00003574 $t Nutrition reviews $x 1753-4887 $g Roč. 75, č. 9 (2017), s. 731-767
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28938795 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180419145558 $b ABA008
- 999 __
- $a ok $b bmc $g 1287815 $s 1007142
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 75 $c 9 $d 731-767 $i 1753-4887 $m Nutrition reviews $n Nutr Rev $x MED00003574
- LZP __
- $a Pubmed-20180404
